Evidence map›Paper›PMID 29330507›Full record

ArticleScientific reports2018

Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation.

Li Gao, Ke-Xin Wang, Yu-Zhi Zhou, Jian-Song Fang, Xue-Mei Qin, Guan-Hua Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. [Research progress of compound injection of traditional Chinese medicine in the treatment of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  17. Identification of Anti-Proliferative Compounds fromMolecules (Basel, Switzerland) · 2022
    Article
  18. Article
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li GaoModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, PR China. gaoli87@sxu.edu.cn.
Ke-Xin WangModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, PR China.
Yu-Zhi ZhouModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, PR China.
Jian-Song FangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Xue-Mei QinModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, PR China. qinxm@sxu.edu.cn.
Guan-Hua DuModern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan, 030006, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compound Kushen Injection (CKI) is a Traditional Chinese Medicine (TCM) preparation that has been clinically used in China to treat various types of solid tumours. Although several studies have revealed that CKI can inhibit the proliferation of hepatocellular carcinoma (HCC) cell lines, the active compounds, potential targets and pathways involved in these effects have not been systematically investigated. Here, we proposed a novel idea of "main active compound-based network pharmacology" to explore the anti-cancer mechanism of CKI. Our results showed that CKI significantly suppressed the proliferation and migration of SMMC-7721 cells. Four main active compounds of CKI (matrine, oxymatrine, sophoridine and N-methylcytisine) were confirmed by the integration of ultra-performance liquid chromatography/mass spectrometry (UPLC-MS) with cell proliferation assays. The potential targets and pathways involved in the anti-HCC effects of CKI were predicted by a network pharmacology approach, and some of the crucial proteins and pathways were further validated by western blotting and metabolomics approaches. Our results indicated that CKI exerted anti-HCC effects via the key targets MMP2, MYC, CASP3, and REG1A and the key pathways of glycometabolism and amino acid metabolism. These results provide insights into the mechanism of CKI by combining quantitative analysis of components, network pharmacology and experimental validation.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicCarcinoma, HepatocellularCaspase 3Cell Line, TumorCell ProliferationCell SurvivalChromatography, High Pressure LiquidDrugs, Chinese HerbalHumansLithostathineLiver NeoplasmsMass SpectrometryMatrix Metalloproteinase 2Proto-Oncogene Proteins c-mycSignal TransductionAntineoplastic Agents, PhytogenicCASP3 protein, humanCaspase 3Drugs, Chinese HerbalkushenLithostathineMatrix Metalloproteinase 2MMP2 protein, humanMYC protein, humanProto-Oncogene Proteins c-mycREG1A protein, human

Identifiers

PMID29330507
PMCPMC5766629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.